AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disorder occurring
in patients of all ages from neonates to the elderly. The current standard treatment protocol
for children with de novo multisystem LCH is vinblastine plus prednisone. This regimen has
never been proven effective for adults in a prospective study, since the only prospective
trial evaluating the efficacy of a vinblastine/prednisone regimen in adults was prematurely
closed due to unacceptable toxicities. A retrospective study showed an advantage for
cytarabine monotherapy compared with vinblastine/prednisone in bone LCH patients. This phase
2, prospective, single-center study is designed to evaluate the efficacy and safety of
cytarabine monotherapy in adults with newly diagnosed MS-LCH or LCH with multifocal single
system (SS-m) involvement.